Logo ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (ANIP) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
ANI Pharmaceuticals, Inc. · Health Care · ref. ETF XLV · 51 calls · price $70.84
🏆JPI 2026 portfoliosSee tracking →
What the company does: ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

📈 ANI Pharmaceuticals, Inc. (ANIP) stock price

$70.84-20.2% over range
Oct 14, 25low $70.19 · high $95.38Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 3 analysts
📊 JPI status : ANI Pharmaceuticals, Inc. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 ANIP price target & analyst consensus — price $70.84

The price target · all analysts combined (3 targets)
Highest target · 1 firm of 3$119+68.0%
Median target · of 3 targets$90+27.0%
Lowest target · 1 firm of 3$85+20.0%
Current price$70.84
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 69% of its targets hit on this sector (51 calls tested). It aims for $119 (+68 %), call made on August 11, 2026, maturing on August 11, 2027 (64 d ago).

The 1 reliable analyst $119+68 %
The 2 other firms $87.50+24 %
How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $119 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 3 ratings (last 6 months)
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about ANI Pharmaceuticals, Inc.? The JPI assistant answers using our backtest data.

🔎 Detailed analyses

✅ Historical analyst reliability on ANIP

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Roth Capital 100% +120.7% 2
Cantor Fitzgerald ↗ 100% +17.2% 2
Canaccord Genuity ↗ 80% +14.2% 5
HC Wainwright & Co. ↗ 69% +22.6% 16
Guggenheim ↗ 53% +4.2% 15
Oppenheimer ↗ 50% +42.0% 4
JP Morgan ↗ 50% -3.7% 2
Raymond James ↗ 42% +2.0% 12
Truist Securities ↗ 33% +2.7% 6

📊 What $1,000 invested in ANI Pharmaceuticals, Inc. would be worth › open the full page

In short — $1,000 invested in ANI Pharmaceuticals, Inc. 10 years ago would be worth $1,785 today, i.e. +6%/yr on average. Best year: 2021 (+59%), worst: 2020 (-53%). Price performance, excluding dividends.

If I'd invested $1,000 in ANI Pharmaceuticals, Inc.

InvestmentWorth todayGain
1 years ago$1,457+46%
3 years ago$2,002+100%
5 years ago$2,774+177%
→ See ANI Pharmaceuticals, Inc.'s full return history + gain calculator

Return by year (ANI Pharmaceuticals, Inc.)

YearReturn$1,000 invested at year start
2026 (YTD)+2%$1,020 (+2%)
2025+43%$1,457 (+46%)
2024+0%$1,461 (+46%)
→ See ANI Pharmaceuticals, Inc.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on ANI Pharmaceuticals, Inc.

Loading news…

📋 All analyst calls on ANIP

Oppenheimer ↗
Sep 23, 26
■ Perform neutral · not a buy · 🎯$85
Price at call : $74.43 — gap to target +14%
Today : $70.84 — gap to target +20%
🎯 on ANIP : no call matured yet · 📊 on Health : 47.4% · +5.9% (95 calls)
in progress (365j)
matures : Sep 23, 27
Guggenheim ↗
Aug 10, 26
▲ Buy · 🎯$119
Price at call : $74.53 — upside +60%
Today : $70.84 — upside +68%
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
in progress (365j)
matures : Aug 10, 27
■ Hold neutral · not a buy · 🎯$90
Price at call : $75.76 — gap to target +19%
Today : $70.84 — gap to target +27%
🎯 on ANIP : no call matured yet · 📊 on Health : 39.9% · -0.9% (148 calls)
in progress (365j)
matures : Aug 10, 27
■ Hold neutral · not a buy · 🎯$91
Price at call : $79.2 — gap to target +15%
Today : $70.84 — gap to target +28%
🎯 on ANIP : no call matured yet · 📊 on Health : 39.9% · -0.9% (148 calls)
in progress (365j)
matures : Jul 17, 27
Guggenheim ↗
Jul 10, 26
▲ Buy · 🎯$124
Price at call : $82.07 — upside +51%
Today : $70.84 — upside +75%
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
in progress (365j)
matures : Jul 10, 27
Guggenheim ↗
Jan 16, 26
▲ Buy · 🎯$124
Price at call : $85.77 — upside +45%
Today : $70.84 — upside +75%
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
in progress (365j)
matures : Jan 16, 27
Barclays ↗
Dec 9, 25
▲ Overweight · 🎯$100
Price at call : $82.03 — upside +22%
Today : $70.84 — upside +41%
🎯 on ANIP : no call matured yet · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Dec 9, 26
Guggenheim ↗
Nov 10, 25
▲ Buy · 🎯$115
Price at call : $88.54 — upside +30%
Today : $70.84 — upside +62%
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
in progress (365j)
matures : Nov 10, 26
See the other 43 calls, newest to oldest
■ Hold neutral · not a buy · 🎯$90
Price at call : $89.79 — gap to target +0%
Today : $70.84 — gap to target +27%
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
in progress (365j)
matures : Oct 9, 26
JP Morgan ↗
Sep 24, 25
▲ Overweight · 🎯$115
Price at call : $94.99 — upside +21%
Today : $70.84 — upside +62%
Expected +21% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 50% (2 calls matureds) · 📊 on Health : 49% · +6.7% (149 calls)
-22.1%
stock -22% · XLV +25%
matured Sep 24, 26
▲ Buy · 🎯$121
Price at call : $97.48 — upside +24%
Today : $70.84 — upside +71%
Expected +24% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
-21.9%
stock -22% · XLV +22%
matured Sep 17, 26
Guggenheim ↗
Sep 8, 25
▲ Buy · 🎯$114
Price at call : $98.46 — upside +16%
Today : $70.84 — upside +61%
Expected +16% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
-28.2%
stock -28% · XLV +20%
matured Sep 8, 26
■ Hold neutral · not a buy · 🎯$77
Price at call : $84.88 — gap to target -9%
Today : $70.84 — gap to target +9%
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
in progress (365j)
matures : Aug 11, 26
▲ Buy · 🎯$93
Price at call : $84.88 — upside +10%
Today : $70.84 — upside +31%
Expected +10% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
-10.7%
stock -11% · XLV +29%
matured Aug 8, 26
▲ Buy · 🎯$84
Price at call : $66.1 — upside +27%
Today : $70.84 — upside +19%
Expected +27% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+24.2%
stock +24% · XLV +18%
matured Jul 10, 26
Guggenheim ↗
May 12, 25
▲ Buy · 🎯$86
Price at call : $62 — upside +39%
Today : $70.84 — upside +21%
Expected +39% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+30.4%
stock +30% · XLV +11%
matured May 12, 26
■ Hold neutral · not a buy · 🎯$65
Price at call : $68.95 — gap to target -6%
Today : $70.84 — gap to target -8%
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
in progress (365j)
matures : Apr 21, 26
Guggenheim ↗
Apr 11, 25
▲ Buy · 🎯$86
Price at call : $68.72 — upside +25%
Today : $70.84 — upside +21%
Expected +25% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+14.0%
stock +14% · XLV +7%
matured Apr 11, 26
▲ Buy · 🎯$94
Price at call : $64.35 — upside +46%
Today : $70.84 — upside +33%
Expected +46% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+15.4%
stock +15% · XLV +2%
matured Mar 17, 26
Jefferies ↗
Mar 14, 25
▲ Buy · 🎯$80
Price at call : $62.49 — upside +28%
Today : $70.84 — upside +13%
Expected +28% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 100% (1 call matured) · 📊 on Health : 49.6% · +9.4% (137 calls)
+15.5%
stock +15% · XLV +4%
matured Mar 14, 26
JP Morgan ↗
Mar 12, 25
▲ Overweight · 🎯$85
Price at call : $61.46 — upside +38%
Today : $70.84 — upside +20%
Expected +38% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 50% (2 calls matureds) · 📊 on Health : 49% · +6.7% (149 calls)
+14.7%
stock +15% · XLV +4%
matured Mar 12, 26
Guggenheim ↗
Mar 5, 25
▲ Buy · 🎯$86
Price at call : $61.05 — upside +41%
Today : $70.84 — upside +21%
Expected +41% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+21.3%
stock +21% · XLV +2%
matured Mar 5, 26
▲ Buy · 🎯$94
Price at call : $58.46 — upside +61%
Today : $70.84 — upside +33%
Expected +61% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+30.2%
stock +30% · XLV +5%
matured Mar 3, 26
▲ Outperform · 🎯$80
Price at call : $59.17 — upside +35%
Today : $70.84 — upside +13%
Expected +35% · Actual +39% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 100% (1 call matured) · 📊 on Health : 54.5% · +7.0% (11 calls)
+38.8%
stock +39% · XLV +8%
matured Dec 11, 25
▲ Buy · 🎯$94
Price at call : $61 — upside +54%
Today : $70.84 — upside +33%
Expected +54% · Actual +43% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+43.1%
stock +43% · XLV +4%
matured Nov 11, 25
■ Hold neutral · not a buy · 🎯$62
Price at call : $59.04 — gap to target +5%
Today : $70.84 — gap to target -12%
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
in progress (365j)
matures : Oct 22, 25
Piper Sandler ↗
Oct 11, 24
▲ Overweight · 🎯$68
Price at call : $57.14 — upside +19%
Today : $70.84 — upside -4%
Expected +19% · Actual +55% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 100% (1 call matured) · 📊 on Health : 45.4% · +6.7% (251 calls)
+55.1%
stock +55% · XLV -8%
matured Oct 11, 25
Raymond James ↗
Sep 18, 24
▲ Outperform · 🎯$83
Price at call : $60.38 — upside +37%
Today : $70.84 — upside +17%
Expected +37% · Actual +60% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 100% (2 calls matureds) · 📊 on Health : 39.7% · -2.1% (219 calls)
+60.3%
stock +60% · XLV -12%
matured Sep 18, 25
▲ Buy · 🎯$94
Price at call : $60.06 — upside +57%
Today : $70.84 — upside +33%
Expected +57% · Actual +59% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+58.8%
stock +59% · XLV -12%
matured Sep 17, 25
■ Hold neutral · not a buy · 🎯$60
Price at call : $54.32 — gap to target +10%
Today : $70.84 — gap to target -15%
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
in progress (365j)
matures : Sep 11, 25
▲ Buy · 🎯$94
Price at call : $57.01 — upside +65%
Today : $70.84 — upside +33%
Expected +65% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+21.1%
stock +21% · XLV -12%
matured Aug 7, 25
▲ Buy · 🎯$94
Price at call : $65.49 — upside +44%
Today : $70.84 — upside +33%
Expected +44% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+0.5%
stock +0% · XLV -8%
matured Jun 26, 25
▲ Buy · 🎯$87
Price at call : $66.03 — upside +32%
Today : $70.84 — upside +23%
Expected +32% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
-8.6%
stock -9% · XLV -11%
matured May 13, 25
Guggenheim ↗
Apr 23, 24
▲ Buy · 🎯$77
Price at call : $65.43 — upside +18%
Today : $70.84 — upside +9%
Expected +18% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+6.4%
stock +6% · XLV -2%
matured Apr 23, 25
Capital One
Mar 15, 24
▲ Overweight
Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 0% (1 call matured) · 📊 unranked overall
-2.5%
stock -3% · XLV +1%
matured Mar 15, 25
Guggenheim ↗
Mar 5, 24
▲ Buy · 🎯$77
Price at call : $65.81 — upside +17%
Today : $70.84 — upside +9%
Expected +17% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
-7.2%
stock -7% · XLV +2%
matured Mar 5, 25
▲ Buy · 🎯$83
Price at call : $66.42 — upside +25%
Today : $70.84 — upside +17%
Expected +25% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
-11.0%
stock -11% · XLV +1%
matured Mar 4, 25
▲ Buy · 🎯$80
Price at call : $67.17 — upside +19%
Today : $70.84 — upside +13%
Expected +19% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
-13.0%
stock -13% · XLV +2%
matured Mar 1, 25
▲ Buy · 🎯$72
Price at call : $59.72 — upside +21%
Today : $70.84 — upside +2%
Expected +21% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
-1.7%
stock -2% · XLV -1%
matured Feb 15, 25
Guggenheim ↗
Oct 19, 23
▲ Buy · 🎯$72
Price at call : $57.44 — upside +25%
Today : $70.84 — upside +2%
Expected +25% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+3.2%
stock +3% · XLV +18%
matured Oct 18, 24
Guggenheim ↗
Sep 13, 23
▲ Buy · 🎯$72
Price at call : $63.61 — upside +13%
Today : $70.84 — upside +2%
Expected +13% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
-8.0%
stock -8% · XLV +17%
matured Sep 12, 24
▲ Buy · 🎯$73
Price at call : $62.5 — upside +17%
Today : $70.84 — upside +3%
Expected +17% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
-1.8%
stock -2% · XLV +16%
matured Aug 21, 24
▲ Buy · 🎯$70
Price at call : $62.5 — upside +12%
Today : $70.84 — upside -1%
Expected +12% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
-1.8%
stock -2% · XLV +16%
matured Aug 20, 24
Guggenheim ↗
Aug 10, 23
▲ Buy · 🎯$72
Price at call : $62.65 — upside +15%
Today : $70.84 — upside +2%
Expected +15% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
-4.7%
stock -5% · XLV +10%
matured Aug 9, 24
Guggenheim ↗
Jul 27, 23
▲ Buy · 🎯$62
Price at call : $52.36 — upside +18%
Today : $70.84 — upside -12%
Expected +18% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+21.3%
stock +21% · XLV +11%
matured Jul 26, 24
▲ Buy · 🎯$60
Price at call : $52.79 — upside +14%
Today : $70.84 — upside -15%
Expected +14% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+17.6%
stock +18% · XLV +9%
matured Jul 20, 24
Guggenheim ↗
May 9, 23
▲ Buy · 🎯$59
Price at call : $43.78 — upside +35%
Today : $70.84 — upside -17%
Expected +35% · Actual +50% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+50.5%
stock +50% · XLV +8%
matured May 8, 24
▲ Buy · 🎯$52
Price at call : $44.41 — upside +17%
Today : $70.84 — upside -27%
Expected +17% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 40% (5 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+47.8%
stock +48% · XLV +7%
matured May 8, 24
Raymond James ↗
May 9, 23
▲ Outperform · 🎯$49
Price at call : $44.41 — upside +10%
Today : $70.84 — upside -31%
Expected +10% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 100% (2 calls matureds) · 📊 on Health : 39.7% · -2.1% (219 calls)
+47.8%
stock +48% · XLV +7%
matured May 8, 24
▲ Buy · 🎯$60
Price at call : $44.41 — upside +35%
Today : $70.84 — upside -15%
Expected +35% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 62% (13 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
+47.8%
stock +48% · XLV +7%
matured May 8, 24
Guggenheim ↗
Mar 1, 23
▲ Buy · 🎯$55
Price at call : $43.82 — upside +26%
Today : $70.84 — upside -22%
Expected +26% · Actual +54% · Reason (≥ +15%) : ✓ Yes
🎯 on ANIP : 67% (12 calls matureds) · 📊 on Health : 64.7% · +17.5% (51 calls)
+54.4%
stock +54% · XLV +14%
matured Feb 29, 24

Frequently asked questions

Should I buy ANI Pharmaceuticals, Inc. stock?

This isn't buy advice. For ANI Pharmaceuticals, Inc., the analyst consensus is "Hold", with an average price target of $90.00 (+27% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on ANI Pharmaceuticals, Inc.). We show the numbers — you decide.

Is it too late to buy ANI Pharmaceuticals, Inc.? How high can it go?

The most bullish analyst target on ANI Pharmaceuticals, Inc. is $119 (+68% above today's price); the average is $90.00. That's the upside they see. Check how reliable those analysts have actually been on ANI Pharmaceuticals, Inc. on our site before trusting it.

Is ANI Pharmaceuticals, Inc. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 9 analysts have a real record on ANI Pharmaceuticals, Inc., the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.

What has ANI Pharmaceuticals, Inc.'s past performance been?

Historical returns and a "how much if I had invested" calculator: ANIP performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)